Record Details

Role of protein tyrosine kinase inhibitors in cancer therapeutics

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Role of protein tyrosine kinase inhibitors in cancer therapeutics
 
Creator Bhise, S B
Nalawade, Abhijit D
Wadhawa, Hitesh
 
Subject Protein tyrosine kinase
Tyrosine kinase inhibitors
Imatinib mesylate
Chronic myeloid leukemia
Acute myeloid leukemia
Anticancer agent
Gastrointestinal stromal tumor
Epidermal growth factor receptor
Vascular endothelial growth factor
 
Description 273-280
Protein tyrosine kinases (PTKs) are critical in
regulating cell growth and differentiation and are deeply involved in several
cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the
treatment of several cancers, and

more than 30 such agents are now in phase I-III
clinical trials. The present review focuses mainly on the development of PTK
inhibitors in clinical trials, with special emphasis on imatinib mesylate, a
rationally designed, potent oral anticancer agent and selective inhibitor for
Abl tyrosine kinase, including Bcr-Abl, C-kit and platelet-derived growth
factor-receptor tyrosine kinases, which has been implicated in several
malignancies, including chronic myeloid leukemia and gastrointestinal stromal
tumour.
 
Date 2016-02-24T09:00:06Z
2016-02-24T09:00:06Z
2004-12
 
Type Article
 
Identifier 0975-0959 (Online); 0301-1208 (Print)
http://hdl.handle.net/123456789/33808
 
Language en_US
 
Rights CC Attribution-Noncommercial-No Derivative Works 2.5 India
 
Publisher NISCAIR-CSIR, India
 
Source IJBB Vol.41(6) [December 2004]